Deutetrabenazine
Brand name: Austedo
Rank #45 of 500 drugs by total cost
$404.1M
Total Cost
60,532
Total Claims
$404.1M
Total Cost
2,499
Prescribers
$6,676
Cost per Claim
655
Beneficiaries
60,971
30-Day Fills
$162K
Avg Cost/Provider
24
Avg Claims/Provider
About Deutetrabenazine
Deutetrabenazine (sold as Austedo) was prescribed 60,532 times by 2,499 Medicare Part D providers in 2023, costing the program $404.1M. At $6,676 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 42 | Atorvastatin Calcium (Atorvastatin Calcium) | $444.6M | 30,263,929 |
| 43 | Osimertinib Mesylate (Tagrisso) | $436.5M | 25,273 |
| 44 | Levothyroxine Sodium (Levothyroxine Sodium) | $435.3M | 20,209,418 |
| 45 | Deutetrabenazine (Austedo) | $404.1M | 60,532 |
| 46 | Linagliptin (Tradjenta) | $403.8M | 519,439 |
| 47 | Macitentan (Opsumit) | $394.6M | 30,889 |
| 48 | Insulin Detemir (Levemir Flexpen) | $376.5M | 548,216 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology